TerminatedPHASE1, PHASE2NCT02963064

JSP191 Antibody Targeting Conditioning in SCID Patients

Studying Severe combined immunodeficiency

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Jasper Therapeutics, Inc.
Principal Investigator: Rajni A. Agarwal-Hashmi, M.D., M.D
Lucile Packard Children's Hospital
Intervention: Humanized anti-CD117 Monoclonal Antibody (JSP191)(biological)
Enrollment: 23 target
Eligibility: 12 years · All sexes
Timeline: 2017 – 2025

Study locations (9)

UCLA Mattel Children's Hospital, Los Angeles, California, United States
Lucile Packard Children's Hospital, Palo Alto, California, United States
UCSF Benioff's Children's Hospital, San Francisco, California, United States
Children's National Medical Center, Washington D.C., District of Columbia, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
University of Minnesota, Minneapolis, Minnesota, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02963064 on ClinicalTrials.gov

Other trials for Severe combined immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Severe combined immunodeficiency →

← Back to all trials